Naveen Atray, M.D., FASN

Naveen Atry
Address:

1111 Exposition Blvd., Suite 300
Sacramento, CA 95815
Ph: 916-564-6232
Fax: 916-564-6242

333 University Av., Suite 120
Sacramento, CA 95825
Ph: 916 929-8564
Fax: 916 929-4529

EDUCATION
Honors and Awards:
Interventional Nephrology Training:
  • Clinical Fellowship, Interventional Nephrology, Louisiana State University Health Sciences Center, Shreveport, LA. July2002- Sept 2002
  • Mini-fellowship in Renal Ultrasonography, Emory University Hospital, Atlanta, GA. Oct 2003.
Post Graduate:
  • Residency, Orthopedics, King George Medical College and Gandhi Memorial Hospital, Sept 1995 – Dec 1996
  • Residency, Internal Medicine, St. Barnabas Hospital/Cornell University, New York, July1997-June 2000
  • Clinical Fellowship, Nephrology and Hypertension, Louisiana State University Health Sciences Center, Shreveport, LA. July 2000-June 2002
  • Clinical Fellowship, Interventional Nephrology, Louisiana State University Health Sciences Center, Shreveport, LA. July 2002- Sept 2002
Graduate:
  • MBBS, King George Medical College, Lucknow, India. 1989-1995.
Specialty Boards:
  • Diplomate in Internal Medicine, American Board of Internal Medicine, 2000-present
  • Diplomate in Nephrology, American Board of Internal Medicine, 2002-present
  • Specialist in Hypertension, American Society of Hypertension, 2003
  • Diplomate, American Board of Hospital Physicians, 2003
  • Diplomate, American College of Ethical Physicians, 2003
  • Fellow of American Society of Nephrology (FASN), 2004
Licensure:
  • California A93005
  • Louisiana 13599R (Inactive)
  • Educational Commission for Foreign Medical Graduates (ECFMG): 0-545-980-5
  • Federal DEA License
  • Medical Council of India
ACADEMIC APPOINTMENTS
  • Assistant Professor, Medicine, LSU-Health Sciences Center, Shreveport, LA, Dec 2002- Mar 2006
  • Associate Professor, Academic Surgery, California Northstate University College of Medicine, Elk Grove, CA, Aug 2014- current
CLINICAL APPOINTMENTS
  • Medical Director, Capital Nephrology Access Center 2008-2014
  • Medical Director, Sunset Community Dialysis, Rancho Cordova, Ca 95742 2008-current
  • Staff Privileges at all DaVita Dialysis Sites
  • Staff Physician, Sutter Medical Center, Sacramento, CA April 2006- current
  • Staff Physician, Dignity Health Care System, Sacramento, CA April 2006- current
  • Staff Physician, Overton Brooks VA Medical Center, Shreveport, LA, Sept 2002-March-2006
  • Staff Physician, LSU Health Sciences Center, Shreveport, LA, Dec 2002-Mar 2006
  • Staff Physician, Willis Knighton Medical Center, LA, Jan 2003-Mar2006
  • Staff Physician, Dialysis Center of Shreveport, Shreveport, LA. Jan 2000- Mar 2006
  • Staff Physician, Dialysis Clinic Inc, Shreveport, LA. Jan 2003-Mar 2006
PROFESSIONAL ACTIVITY

Professional Affiliations:
  • American Society of Diagnostic and Interventional Nephrology
  • American Society of Hypertension
  • American Society of Nephrology
  • American Federation of Medical Research
National Committees:
  • Member, Private Nephrologists Advisory Group, American Society of Nephrology, 2007-2010
  • Member, Kidney Council- American Heart Association – 2003 to 2006
  • Council Member, American Society of Diagnostic and Interventional Nephrology – 2004 to 2010
  • Chair, Communications Committee, American Society of Diagnostic and Interventional Nephrology 2004-2010
Hospital Committees:
  • Hospital Pharmacy & Therapeutics Committee: Jan 2003-Mar 2006
National Meetings:
  • Chair: Abstract Session, Second Annual Scientific Meeting, American Society of Diagnostic and Interventional Society, San Antonio, TX, April 2006
  • Invited Faculty: Post-Graduate Workshop, National Kidney Foundation Spring Meeting, Chicago, April 2006
  • Faculty Speaker, Third Annual Scientific Meeting, American Society of Diagnostic and Interventional Nephrology, Puerto Rico, May 2007

SPEAKING ENGAGEMENTS
  • Invited speaker at Al Hayat Clinic, Muscat, Oman: Recent Trends in Management of Hypertension, June 2003
  • Invited speaker at Ibri General Hospital, Ibri, Oman: Update on Management of Hypertension June 2003
  • VA Regional Teleconference on Management of Chronic Kidney Disease, Feb 2004
  • Grand rounds:
    • Contrast Nephropathy: Shifting Paradigms, LSU-HSC, Shreveport, LA, Nov 2004.
    • Integrated Vascular Access Care: Role of Interventional Nephrologist, Johns Hopkins Medical Center, Baltimore, MD, Sept 2005.
    • BMP-7 at Cross Roads of Renal Repair and Renal Regeneration Therapy, LSU-HSC, Shreveport, LA, Jan 2006
  • Invited speaker: ANNA Sacramento chapter annual meting: Integrated Vascular Access Care: Role of Dialysis Providers, Sacramento, Aug 2006
  • Faculty Speaker: National Kidney Foundation, Spring Clinical Meeting: When AV Fistula Clot: Approach Same or different as AV Graft, April 2007, Orlando, FL
TEACHING ACTIVITY
  • Medical Students: History & Physical, bedside teaching, Sophomore lectures and small group sessions
  • Medical Residents: Didactic lecture and bedside teaching, procedures
  • Nephrology Fellows: Didactic lectures, Journal clubs, Interventional procedures, clinical teaching
GRANTS and AWARDS
  • Paul Teschan Research Fund: Role Of Bone Morphogenic Protein-7 (BMP-7) And Cytokine Gene Polymorphisms In Renal In Transplant Rejection. Principal Investigator. $50,000 / year for three years (Awarded 2004, Renewed 2005).
  • Iron Dextran Infusion and Oxidant Stress in Chronic Kidney Disease. (LOI approved for Merit review)
  • Honors in Pathology 1992
  • Colonel Scott Gold Medal in Pathology 1994
  • Travel Fellowship, American Society of Nephrology, 2001, San Francisco, CA
  • Honored by Gulf Chapter of American Society of Hypertension for “Designated Specialist in Clinical Hypertension” in Jan 2004
  • Young Faculty Research Award by American Federation of Medical Research (AFMR) and Southern Society of Clinical Investigation (SSCI), Feb 2004
BIOGRAPHICAL LISTINGS
  • Marquis Who’s Who in Medicine and Healthcare
  • Top Physicians in United States 2004
PUBLICATIONS
  1. Longitudinal Study of Hemodialysis Graft Stenosis: Role of Progressive Stenosis in Thrombosis. Naveen K. Atray, William Paulson, S. Ram. Journal of American Society of Nephrology: Volume 12, Sept 2001.
  2. Minimal Change Glomerulonephritis following a Wasp-sting. F. Zaman, S. Saccaro, S. Latif, Naveen K. Atray. American Journal of Nephrology. Nov-Dec 2001; 21(6):486-9.
  3. Accurate Prediction of Hemodialysis Graft Thrombosis by Multivariate Logistic Regression. W.D.Paulson, Naveen K Atray, S.J. Ram. Journal of American Society of Nephrology: Volume 12, Sept 2001.
  4. Association Between Blood Pressure, Ultrafiltration, And Hemodialysis Graft Thrombosis: A Multivariable Logistic Regression Analysis. Paulson WD, Ram SJ, Faiyaz R, Caldito GC, Atray NK. Am J Kidney Dis. 2002 Oct; 40(4): 769-76.
  5. Blood Flow Inaccurately Predicts Hemodialysis Graft Thrombosis: Insight From Two Case Reports. Naveen K. Atray, William Paulson. Seminars in Dialysis 2002: Sept-Oct; 15(5): 370-4.
  6. Aging Veterans: Outcome in Dialysis Population. Vachharajani TJ, Atray N, Johnson A, Hays B, Maeweathers G. American Journal of Kidney Diseases. Vol 41(4) A36:2003.
  7. Interventional Nephrology: An Experience at Veterans Affairs Hospital. Tushar Vachharajani, Naveen Atray. American Journal of Kidney Diseases. Vol 41(4) A37:2003.
  8. Fluoroscopy assisted placement of peritoneal dialysis catheters by Nephrologists. F.Zaman, A. Pervez, N. Atray, A. Aslam, S. Murphy, K. Abreo. American Journal of Kidney Diseases. Vol 41(4) A48:2003.
  9. Total Dose Iron Dextran Infusion in Chronic Kidney Disease: Safety and Efficacy. Naveen K Atray, Stephen Simpson, Gail Maeweathers, Alice Johnson, Sharon Drayton-Moran. Journal of American Society of Nephrology: Volume 14, Nov 2003 (241).
  10. Pullback Pressure Measurements as a Predictor of Successful Angioplasty in Failing Hemodialysis Vascular Access. Fahim Zaman, Aslam Pervez, Naveen K. Atray, Asim Aslam, Kenneth D. Abreo. Journal of American Society of Nephrology: Volume 14, Nov 2003 (241).
  11. Interventional Nephrology in Federal Health Care System. Naveen K Atray, Tushar J Vaccharajani. American Journal of Kidney Diseases: 2003 November   42(5):1105.
  12. Post transplant lymphocele: a single centre experience. Atray N.K.; Moore F.; Zaman F.; Caldito G.; Abreo K.; Maley W.; Zibari G.B. Clinical Transplantation, August 2004, Volume 18, p. 46-49(4).
  13. Nephrology Ethics: “No Dialysis” As a Treatment Option. T.J. Vachharajani, N.K. Atray. Hemodialysis International: Jan 2004 8 (1):94.
  14. Is Dialysis Always Justified? Ethics and Economics. M. Qadri, N.K. Atray, T.J. Vachharajani. Hemodialysis International; Jan 2004 8(1): 93.
  15. Fatal Lactic Acidosis Associated with Non-Hodgkin’s Lymphoma, Interferon, Ribavirin. Mashood Qadri, Naveen K. Atray, Tushar J Vachharajani. Journal of Investigative Medicine Vol 52, #1Jan 2004.
  16. Modern Nephrology: “One-Stop-Shop” Approach. Tushar J. Vachharajani and Naveen K. Atray. Journal of Investigative Medicine Vol 52, #1Jan 2004.
  17. Celiac Sprue and Renal Cell Carcinoma: A Unique Association. Mashood Qadri, Naveen K Atray and Tushar Vachharajani. Journal of Investigative Medicine Vol 52, #1Jan 2004.
  18. Xenotransplantation (Book-Chapter). Naveen Atray, Tushar J Vachharajani, Monika Ray. E-Medicine. http://www.emedicine.com/. Volume 15 (#15).
  19. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Abosaif NY, Arije A, Atray NK, Baade KJ et al. Am J Kidney Dis. 2004 May; 43(5 Suppl 1):S1-290.
  20. Nephrology education clinic for early chronic kidney disease. Vachharajani TJ, Atray NK, Hays B. Semin Dial. 2004 Jul-Aug; 17(4):320-1.
  21. Vascular Access Conundrum. Vachharajani TJ, Atray NK. Semin Dial. Volume 18 Issue 2 Page 161  - March 2005.
  22. Invasive and innovative nephrology. Vachharajani TJ, Atray NK. Renal Failure, Volume 27, Issue 3, May 2005.
  23. Does treating obesity stabilize chronic kidney disease? Agnani S, Gupta R, Vachharajani VT, Atray NK, Vachcharajani T. BMC Nephrol. 2005 Jun 15; 6(1):7.
  24. Fluoroscopy-assisted placement of peritoneal dialysis catheters by nephrologists. Zaman F, Pervez A, Atray NK, Murphy S, Work J, Abreo KD. Semin Dial. 2005 May-Jun; 18(3):247-51.
  25. A Large Splenic Cyst: “Incidentalocyst”. Sequeira A, Atray NK, Vachharajani TJ. South Med J. 2005 Oct; 98(10):1054-5.
  26. Interventional nephrology in a federal hospital: economics of health care. Vachharajani TJ, Atray NK. Semin Dial. 2006 Sep-Oct; 19(5):421-4.
  27. New Tunnelled Hemodialysis Catheter Placement through Old Exit Site, Atray NK, Arif Asif, Semin Dial, Volume 21, Issue 1, Page 97-99, Jan 2008.
  28. Which direction is right for vascular access surveillance? A debate. Kenneth Abreo, Michael Allon, Arif Asif, Atray NK,, Anotole Basarab, Laura M. Dember, Bardley S. Dixon, Marie DeVita, James Kaufman, Brian M. Murray, Vo D. Nguyen, Sundanda J. Ram, Tushar Vachharajani, Thomas M. Vassly, John J. White, Jack Work. Nephrology New & Issues June 2010.
  29. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engle J Med. 2013 Dec 26;369(26):2492-503. doi: 10.1056/NEJMoa1306033. BEACON Trial Investigators
  30. Outcomes of cephalic arch stenosis with and without stent placement after percutaneous balloon angioplasty in hemodialysis patients
    Dukkipati R, Lee L, Atray N, Kajani R, Nassar G, Kalantar-Zadeh K.
    Semin Dial. 2015 Jan;28(1):E7-E10. doi: 10.1111/sdi.12310. Epub 2014 Oct 9.
PAPERS PRESENTED

Oral:
  1. Natural History of AV Graft Stenosis. Red River Vascular Symposium. Shreveport, LA. August 2001.
  2. Various Treatment Modalities to treat Post-kidney transplant Lymphocele: A Single Center Experience. South Eastern Organ Procurement Foundation (SEOPF) Annual Scientific Session. Atlanta, GA. September 2003.
  3. Efficacy And Safety of Total Dose Iron Dextran In Predialysis Population. Annual Regional Meeting of American Federation of Medical Research. New Orleans, LA. February 2004.
  4. Support Vector Machines to Determine the Dose of Hemodialysis. Twenty-Sixth Annual International Conference of the IEEE Engineering in Medicine and Biology Society. San Francisco, CA. September 2004.
Poster:
  1. Aging Veterans: Outcome in Dialysis Population. Vachharajani TJ, Atray N, Johnson A, Hays B, Maeweathers G. National Kidney Foundation Annual Clinical Meeting, Dallas, Texas 2003.
  2. Interventional Nephrology: An Experience at Veterans Affairs Hospital. Vachharajani TJ, Atray N, Pervez A, Zaman F, Work J, Abreo K. National Kidney Foundation Annual Clinical Meeting, Dallas, Texas 2003.
  3. Fluoroscopy assisted placement of peritoneal dialysis catheters by  Nephrologists. F.Zaman, A. Pervez, N. Atray, A. Aslam, S. Murphy, K. Abreo. National Kidney Foundation Annual Clinical Meeting, Dallas,  Texas 2003.
  4. Longitudinal Study of Hemodialysis Graft Stenosis: Role of Progressive Stenosis in Thrombosis. Naveen K. Atray, William Paulson, S. Ram. World Congress of Nephrology. San Francisco, Oct 2001.
  5. Accurate Prediction of Hemodialysis Graft Thrombosis by Multivariate Logistic Regression. W.D.Paulson, Naveen K Atray, S.J. Ram. World Congress of Nephrology. San Francisco, Oct 2001.
  6. Total Dose Iron Dextran Infusion in Chronic Kidney Disease: Safety and Efficacy. Naveen K Atray, Stephen Simpson, Gail Maeweathers, Alice Johnson, Sharon Drayton-Moran. ASN Renal Week, San Diego Nov 2003.
  7. Pullback Pressure Measurements as a Predictor of Successful Angioplasty in Failing Hemodialysis Vascular Access. Fahim Zaman, Aslam Pervez, Naveen K. Atray, Asim Aslam, Kenneth D. Abreo. ASN Renal Week, San Diego Nov 2003.
  8. Is Dialysis Always Justified: Ethics and Economics. Mashood Qadri, Naveen K. Atray, Tushar Vachharajani 24th Annual Dialysis Conference, San Antonio, Feb 2004.
  9. Diagnosis and clinical significance of graft-to-vein fistulas associated with synthetic hemodialysis grafts. Tushar J. Vachharajani, Naveen K Atray, Sunanda Ram and Kenneth D. Abreo. 24th Annual Dialysis Conference, San Antonio, TX, Feb 2004.
  10. Nephrology ethics: “No dialysis” as a treatment option: Tushar J. Vachharajani and Naveen K. Atray. 24th Annual Dialysis Conference, San Antonio, TX, Feb 2004.
  11. Fatal Lactic Acidosis Associated with Non-Hodgkin’s Lymphoma, Interferon, Ribavirin. Mashood Qadri, Naveen K. Atray, Tushar J Vachharajani. AFMR (Southern Region). Feb 2004, New Orleans, LA.
  12. Celiac Sprue and Renal Cell Carcinoma: A Unique Association. Mashood Qadri, Naveen K Atray and Tushar Vachharajani. American Federation of Medical Research. Feb 2004, New Orleans, LA.
  13. Renal Cell Carcinoma Presenting as Nasal Polyp. Stephen Simpson, Naveen K. Atray, Tushar J. Vachharajani AFMR (Southern Region) 2004.
  14. Modern Nephrology: “One-Stop-Shop” Approach. Tushar J. Vachharajani and Naveen K. Atray. American Federation of Medical Research (Southern Region) meeting, New Orleans, LA, Feb 2004.
  15. A Large Splenic Cyst: "Incidentalocyst". Adrian Sequeira, Naveen Atray, Tushar Vachharajani. Society of General Internal Medicine. Annual Meeting, Chicago, IL. May 2004.
  16. Artificial Intelligence Based Prediction of Outcome of Acute Renal Failure in Critically Ill Patients. Naveen K. Atray, Tushar J Vachharajani, Monika Ray. 37th annual American Society of Nephrology Annual Scientific Meeting. October 2004, St Louis, MO.
  17. Financial impact of interventional nephrology in a federal health care facility. Tushar Vachharajani and Naveen K. Atray. 37th annual American Society of Nephrology Annual Scientific Meeting. October 2004, St Louis, MO.
  18. Obesity and Acute Renal Failure in Critically Ill Patients. Tushar J Vachharajani, Naveen K. Atray, Runhua Shi, Vidula Vachharajani. 37th American Society of Nephrology Annual Scientific Meeting. October 2004, St Louis, MO.
  19. Erythropoietin and cytokine gene polymorphism: Sunanda Ram, Naveen Atray and Tushar Vachharajani. SSCI, Southern Regional Meeting, Mar 2005, New Orleans, LA.
  20. Cuffed Tunneled catheter recirculation with reversal of ports comparing two different brands: Sachdeva B, Naveen Atray, Tushar Vachharajani, SSCI, Southern Regional Meeting, Mar 2005, New Orleans, LA.
  21. Non-Hodgkin’s Lymphoma presenting as acute renal failure and accelerated hypertension. Adrian Sequeira, Tushar Vachharajani and Naveen Atray. SSCI, Southern Regional Meeting, 2005.
  22. Transposed Forearm Fistulae: Successful and Creative Improvisation. Sachdeva B, Atray NK, Vachharajani TJ. 38th American Society of Nephrology Annual Scientific Meeting. Nov 2005, Philadelphia, PA.
Clinical Trial Participation A Phase III, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multi-Center Trial Evaluating the Efficacy and Safety of XXX in Adult Patients on Chronic Hemodialysis. Naveen Atray, MD as PI

A Phase III, Randomized, Active-Controlled, Open-Label, Multi-Center Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Hemodialysis Patients previously treated with Epogen. Naveen Atray, MD as PI

A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI

A Phase II, Randomized, Double-Blind Placebo-Controlled, Multi-Center, to Evaluate the Safety and Efficacy of XXX in Patients with Nephropathy Due to Type 2 Diabetes. Naveen Atray, MD as PI

Patient FOCUS Group for Qualitative Assessment of Anemia Associated with Chronic Kidney Disease. Naveen Atray, MD as PI

A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of XXX in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease who are on Dialysis and who have Inadequate Glycemic Control. Naveen Atray, MD as PI

A Phase II Study of the Safety and Efficacy of XXX Injection for the Maintenance Treatment of Anemia in Subjects with Chronic Renal Failure on Hemodialysis, or Do Not Require Dialysis and Previously Treated with Darbepoetin Alfa. Naveen Atray, MD as PI

An Observer-Blinded, Randomized Study Comparing the Safety and Immunogenicity of XXX to Licensed Vaccine (Energix-B®) among Adults (18-75 years of age) with Chronic Kidney Disease (CKD). Naveen Atray, MD as PI

A Randomized Evaluation of Efficacy and Safety of XXX in Patients with Iron Deficiency Anemia and Impaired Renal Function. Naveen Atray, MD as PI

A Phase 2, Multicenter, Randomized, Double-Blind Study of the Safety, Clinical Activity and Pharmacokinetics of XXX Versus Placebo in Subjects with Autosomal Dominant Polycysstic Kidney Disease (ADPKD). Naveen Atray, MD as PI

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a XXX in Adults with Type 2 Diabetes and Overt Nephropathy. Naveen Atray, MD as PI

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX in Patients with Systemic Lupus Erythematosus (SLE). Naveen Atray, MD as PI

A Phase IV, Long Term, Observational Safety Study in End Stage Renal Disease Subjects Treated with XXX. Naveen Atray, MD as PI

Observational Study in Patients with Chronic Kidney Disease and Type 2 Diabetes: Identifying Patients: Identifying Patients with Estimated GFR Between 15 and 30 mL/min/1.73m². Naveen Atray, MD as PI

February 2011: BPV-08-002 – Prospective, Multi-Center, Randomized, Concurrently-Controlled Study of the Fluency® Plus Endovascular Stent Graft in the Treatment of In-Stent Restenosis in the AV Access Venous Outflow Circuit (RESCUE)
Sponsor: Bard Peripheral Vascular, Inc.
Naveen Atray, MD as PI

March 2011: QWC01-MN-01 – A Randomized, Placebo-Controlled, Double-Blind Study of H.P. Acthar® Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN)
Sponsor: Questcor Pharmaceuticals, Inc.; Naveen Atray, MD as PI

May 2011: 402-C-0903 – Bardoxolone Methyl Evaluation in patients with Chronic Kidney Disease and Type 2 Diabetes; The Occurrence of Renal Events (BEACON)
Sponsor: Reata Pharmaceuticals, Inc; Naveen Atray, MD as PI

August 2011: AFX01-18 – A Phase 3b Single-Arm, Conversion Study from Epoetin alfa to Monthly Peginesatide Injection in Patients with Chronic Kidney Disease on Dialysis
Sponsor: Affymax, Inc;

August 2011: EOPE-10-13 – A Therapeutic-Equivalence Study Comparing the Efficacy and Safety of Subcutaneous Epoetin Hospera and Epoetin Alfa (Amgen) in Patients with Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. Sponsor: Hospira, Inc.; Naveen Atray, MD as PI

July 2012: ISG2012 – An Open Label Equivalence Study Comparing 50mg Weekly to 100mg Biweekly Maintenance Intravenous Iron Sucrose to Assess Impact in Ferritin, Transferrin Saturation, and Hemoglobin in Hemodialysis Patients
Sponsor: DaVita Clinical Research; Naveen Atray, MD as PI

October 2012: 20110226 – START-CKD: Strategies Using Darbepoetin alfa to Avoid Transfusions in Chronic Kidney Disease
Sponsor: Amgen Inc.; Naveen Atray, MD as PI

October 2012: CTAP101-CL-3001 – A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects with Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency
Sponsor: Cytochroma, Inc.; Naveen Atray, MD as PI

November 2012: HX575-307 – Randomized, Double-Blind, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin alfa vs. US Licensed Epoetin alfa (Epoetin®/Procrit®) in the Treatment of Anemia Associated with Chronic Kidney Disease
Sponsor: Sandoz, Inc.; Naveen Atray, MD as PI

December 2012: ZS -003 – A Phase 3 Multicenter, Two-Phase, Multi-Dose, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate), an Oral Sorbent, in Subjects with Mild to Moderate Hyperkalemia
Sponsor: ZS Pharma, Inc.; Naveen Atray, MD as PI

January 2013: RLY5016-301 – A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia
Sponsor: Relypsa, Inc.; Naveen Atray, MD as PI

April 2013: D5611C00001 – A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety and Tolerability of AZD1722 in End Stage Renal Disease Patients on Hemodialysis
Sponsor: Ardelyx, Inc.; Naveen Atray, MD as PI

May 2013: D5610C00001 – An Exploratory Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of ASD1722 in CKD patients with Type 2 Diabetes Mellitus and Albuminuria
Sponsor: Ardelyx, Inc.; Naveen Atray, MD as PI

May 2013: M11-352 – A Randomized, Multcountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SJONAR: Study of Diabetic Nephropathy and Atrasentan
Sponsor: AbbVie Inc.; Naveen Atray, MD as PI

June 2013: 20120229 – A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects with Chronic Kidney Disease on Hemodialysis
Sponsor: Amgen Inc.; Naveen Atray, MD as PI

July 2013: CTAP101-CL-3003 - A Long-term Safety and Efficacy study of CTAP101 Capsules in Subjects with Stages 3 or 4 Chronic Kidney Disease Secondary Hyperparathyroidism and Vitamin D insufficiency (Extension Study CTAP101-CL-3001)
Sponsor: OPKO IP Holdings II, Inc.; Naveen Atray, MD as PI

August 2013: AKB-6548-CI-0007 – Phase 2b randomized, double-blind, placebo-controlled study to assess the Pharmacodynamic response, safety, and tolerability to 20 weeks of oral dosing of AKB-6548 in subjects with anemia secondary to chronic kidney disease (CKD), GFR categories G3A-G5 (Stages 3, 4 and 5) (Pre-dialysis)
Sponsor: Akebia therapeutics, Inc.; Naveen Atray, MD as PI; Elena Gelfand, MD, Ratnaji Nallamothu, MD as sub-investigators

October 2013: AMAG-FER-CKD-401: Ferumoxytol for Anemia of CKD Trial (FACT): A Phase IV, Open-Label, Multicenter Trial, With MRI Substudy, of Repeated Doses of Ferumoxytol Compared With Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA) in Chronic Kidney Disease (CKD) Patients on Hemodialysis
Sponsor: AMAG Pharmaceuticals, Inc.; Naveen Atray, MD as PI; Elena Gelfand, MD, Ratnaji Nallamothu, MD, David Pai, MD, and Ganesh Kambhampati, MD as sub-Investigators.

Jan 2014: 2012-02-02-NVO-MIA Randomized Controlled Study of the Effect of a Needle Phobia Intervention With or Without Synera® on Conversion from Central Venous Catheters to Arteriovenous Fistula or Graft
Sponsor: DaVita Clinical Research; Naveen K. Atray, M.D. as PI; Elena Gelfand, M.D., Ratnaji Nallamothu, M.D., Ganesh Kambhampati, M.D. as Sub-investigators

April 2014: 20130374: Study Protocol for the Validation of the Nausea/Vomiting Symptom Assessment (NVSA) Patient-Reported Outcome Instrument Among Chronic Kidney Disease Patients on Dialysis With Secondary Hyperparathyroidism
Sponsor: AMGEN, Inc.; Naveen Atray, MD as PI.

June 2014: VPI-CLN-201-AD: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes
Sponsor: Vascular Pharmaceuticals, Inc.; Naveen Atray, MD as PI; Elena Gelfand, MD, and Ganesh Kambhampati, MD as sub-Investigators.

June 2014: D5613C00001 A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis
Sponsor: Astra Zeneca AB; Naveen K. Atray, M.D. as PI; Elena Gelfand, M.D.,
David Pai, M.D., Ganesh Kambhampati, M.D. as Sub-investigators

June 2014: 28431754DNE3001-Phase 3 Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
Sponsor: Janssen Research & Development; Naveen Atray, MD as PI; Elena Gelfand, MD, and Ganesh Kambhampati, MD, as Sub-Investigators

August 2014: ZS-005 - A Phase 3 Multicenter, Multi-dose, Open-label Maintenance Study to Investigate the Long-term Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), an Oral Sorbent, in Subjects With Hyperkalemia, Including a Randomized, Double-blind, Placebo-controlled, Withdrawal Study
Sponsor: ZS Pharma; Atray, MD as PI; Elena Gelfand, MD, and Ganesh Kambhampati, MD, as Sub-Investigators

September 2014: KRX-0502-306 - A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia in Adult Subjects with Non-Dialysis Dependent Chronic Kidney Disease
Sponsor: Keryx Biopharmaceuticals, Inc; Naveen Atray, MD as PI; Elena Gelfand, MD, and Ganesh Kambhampati, MD as sub-investigators

April 2015: D5740C00001 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
Sponsor: Astra Zeneca: Ganesh Kambhampati, MD as PI; Naveen Atray, MD, Elena Gelfand, MD as sub-investigators

June 2015: D5740C00002 - A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Sponsor: Astra Zeneca: Ganesh Kambhampati, MD as PI; Naveen Atray, MD, Elena Gelfand, MD, David Pai, MD, Ratnaji Nallamothu, MD as sub-investigators

Our Locations

CNMG

Capital Nephrology Medical Group

333 University Av., Suite 120

Sacramento, CA 95825

Tel: 916-929-8564

Fax: 916-929-4529



View Office Locations in a larger map

We care about your and your family members' health and helping you make wise care decisions.

Understanding what kind of care you and your family members need is important.

If you think you or your family member has a medical or psychiatric emergency, call 911 or go to the nearest hospital. Do not attempt to access emergency care through this website.